Glepaglutide efficacy and safety in short bowel syndrome patients without or with colon-in-continuity: Results of ease sbs 1 phase 3 trial

Rationale: Reducing parenteral support (PS) and achieving enteral autonomy (EA) are goals for short bowel syndrome (SBS) patients with intestinal failure (IF). Glepaglutide, a novel long-acting GLP-2 analog, was assessed for efficacy and safety in reducing PS needs in SBS-IF patients without or with colon-in-continuity (CiC).

Source: Clinical Nutrition ESPEN - December 1, 2023 Category: Nutrition Authors: U.F. Pape, T. Vanuytsel, S. Subramanian, F. Joly, G. Wanten, G. Lamprecht, M. Kunecki, F. Rahman, T.S. Nielsen, L.B. Graff, M. Berner-Hansen, D.F. Mercer, P.B. Jeppesen Source Type: research